Fig. 4: Decrease of peripheral virus shedding in meganuclease-treated mice.
From: Gene editing for latent herpes simplex virus infection reduces viral load and shedding in vivo
a Experimental timeline of ocular infection, meganuclease treatment and viral reactivations with JQ1. b, c HSV loads and d, e, AAV loads in SCGs (b; p = 0.0016, 0.0012, and <0.0001 for 0.6, 1.2, and 1.8 × 1012, respectively, d) and TGs (c; p = 0.068, 0.0025 and 0.0016 for 0.6, 1.2, and 1.8 × 1012, respectively, e) in control infected mice (n = 11) and infected mice treated with dual therapy delivered with 0.6 (n = 12), 1.2 (n = 12), or 1.8 (n = 12) × 1012 total vg AAV dose. Percent decrease of HSV loads in treated mice compared to control mice and statistical analysis (ordinary one-way Anova, multiple comparisons with ns: not significant, **p < 0.01, ****p < 0.0001) are indicated. f–i Virus titers in eye swabs collected daily from day 1 to 4 after each weekly JQ1 reactivation from control infected mice (f) and infected mice treated with dual therapy delivered with 0.6 (g), 1.2 (h), or 1.8 (i) ×1012 total vg AAV dose. j–l Area under the curve (AUC) analysis of virus shedding after first (j), second (k), and third (l) JQ1 reactivation from control infected mice (n = 11) and infected mice treated with dual therapy delivered with 0.6 (n = 12), 1.2 (n = 12) or 1.8 (n = 12) × 1012 total vg AAV dose. p values (unpaired, ordinary one-way Anova, with multiple comparisons) compared virus shedding between treatment groups and the control group. Each graph shows individual and mean values with standard deviation. Source data are provided as a Source Data file.
